Drug
Florbetapir clinical trials
Also written Amyvid and 18F-AV-45.
- studies test it
- 37
- open now
- 2
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the florbetapir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Amyvid
- 30
Development codes
Studies by the year they started
36 studies that test it; most in 2012 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 5 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 9
- Phase 2
- 10
- Phase 3
- 6
- Phase 4
- 7
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 10
Avid Radiopharmaceuticals (27) · Invicro (2) · University of California, San Francisco (1) · Centre Hospitalier Universitaire, Amiens (1) · University Hospital, Tours (1) · Institute for Neurodegenerative Disorders (1) · Columbia University (1) · Universidad Central del Caribe (1)
Often tested with
Tested in the same studies.
Flortaucipir (1) · Pittsburgh compound B (1) · Fluorodeoxyglucose F18 (1) · Florbenazine F 18 (1) · Sulfur Hexafluoride (1) · MK-6240 (1) · Gadoterate meglumine (1) · Florzolotau F-18 (1)
Studies
Open first, then newest update. How each study uses florbetapir is read from its arms, and is right about nine times in ten.
Testing it · 37
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and TauNot yet recruitingPhase 1Columbia UniversityNCT06600880Written as Amyvid
- B-amyloid as a Marker for GBM BioimagingNot yet recruitingPhase 2Universidad Central del CaribeNCT05820191Written as Amyvid, Intravenous Solution
- Cerebral Amyloid Imaging Using Florbetapir (AV-45)CompletedPhase 3Centre Hospitalier Universitaire, AmiensNCT02813434Written as florbetapir
- Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)CompletedNot applicableUniversity Hospital, ToursNCT01962753Written as 18FAV45
- Effects of Brain Beta-Amyloid on Postoperative CognitionActive, not recruitingPhase 4University of California, San FranciscoNCT01606488Written as Florbetapir F 18 (18F-AV-45)
- Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07CompletedPhase 3Avid RadiopharmaceuticalsNCT01447719Written as florbetapir F 18
- Plasma P-tau2017 and Quantitative Amyloid PET ImagingCompletedPhase 1InvicroNCT05164536Written as Amyvid
- Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)CompletedPhase 3Avid RadiopharmaceuticalsNCT01565382Written as florbetapir F 18
- Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS PatientsCompletedPhase 4Institute for Neurodegenerative DisordersNCT01767493Written as [18F]Florbetapir PET imaging
- The Role of F-18 Florbetapir in the Early Detection of Cardiac AmyloidosisTerminatedPhase 4The Cleveland ClinicNCT03040427Written as F-18 florbetapir
- Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired SubjectsCompletedEarly Phase 1Avid RadiopharmaceuticalsNCT04474405Written as Florbetapir F 18
- Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET ExaminationStatus unknownPhase 2Chang Gung Memorial HospitalNCT04305210Written as 18F-florbetapir
- Phase 1 Test-retest Evaluation of [18F]MNI-958 PETCompletedPhase 1InvicroNCT03545789Written as [18F]MNI-958
- Clinical Evaluation of Florbetapir F 18 (18F-AV-45)CompletedPhase 2Avid RadiopharmaceuticalsNCT01518374Written as Florbetapir F 18
- Florbetapir Calibration to the Centiloid ScaleCompletedPhase 1Avid RadiopharmaceuticalsNCT02120664Written as Florbetapir (18F)
- Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclineCompletedPhase 4Avid RadiopharmaceuticalsNCT01703702Written as florbetapir (18F)
- Evaluation of Reader Training ProcessesCompletedPhase 4Avid RadiopharmaceuticalsNCT02051790Written as florbetapir F 18
- The Feasibility of Florbetapir Quantitation in EuropeCompletedPhase 4Avid RadiopharmaceuticalsNCT02107599Written as Florbetapir (18F)
- The Feasibility of Florbetapir QuantitationCompletedPhase 4Avid RadiopharmaceuticalsNCT01946243Written as Florbetapir F18
- Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese PhysiciansWithdrawnNot applicableAvid RadiopharmaceuticalsNCT02029547Written as Florbetapir (18F)
See all 37 studies that test florbetapir →
Given in every arm · 5 — florbetapir is usual care beside what is tested
- A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's DiseaseCompletedPhase 1Eli Lilly and CompanyNCT03019536Written as Florbetapir F 18
- Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD SubjectsCompletedPhase 2/3Avid RadiopharmaceuticalsNCT02016560Written as florbetapir F 18
- 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic EncephalopathyCompletedPhase 2Avid RadiopharmaceuticalsNCT02079766Written as florbetapir F 18
- Imaging Characteristics of a Follow-up 18F-AV-1451 ScanTerminatedPhase 2Avid RadiopharmaceuticalsNCT02051764Written as Florbetapir F 18
- Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseWithdrawnPhase 2SanofiNCT02667496Written as Florbetapir F18
Codes
What other systems call florbetapir · ClinicalTrials.gg INT005524
- MeSH (NLM) C545186florbetapirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6867Q6IKODFLORBETAPIRConfirmed NLM, Wikidata
- RxNorm 1427225Confirmed FDA, Wikidata
- Wikidata Q27264221florbetapirConfirmed NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545186 | florbetapir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6867Q6IKOD | FLORBETAPIR | Confirmed NLM, Wikidata |
| RxNorm | 1427225 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27264221 | florbetapir | Confirmed NLM, Wikidata |
Also registered as florbetapir f-18 (UNII 6W15Z5R0RU · RxNorm 1427224).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.